In patients with CKD anemia not requiring dialysis, Roxadustat elevates Hb levels in a dose-dependent manner, significantly decreases ferritin levels, and briefly increases endogenous EPO levels within or near the physiological range, compared to placebo at high doses. This evidence concerns the gene GSTM1 and chronic kidney disease.